Merck’s $11 Billion Harpoon Acquisition Isn’t About Today’s Revenue
On Tuesday, Merck stunned the market with news it would acquire Harpoon Therapeutics for just over $11 billion, more than 24 times Harpoon’s current-year sales. That eye-watering multiple gave plenty of analysts pause. Merck is paying a premium one usually sees for late-stage oncology assets with near-certain regulatory approval, yet Harpoon’s lead T cell engager, HPN328, is still two years out from a pivotal readout and hasn’t generated commercial revenue. This marks a notable shift from Merck’s typical playbook of bolt-on, derisked deals.
The deal’s structure raises eyebrows too. Most of the payout is upfront, with just $1 billion in milestones tied to regulatory approvals. On investor calls, Merck leadership leaned hard on the "platform potential" narrative and the strategic imperative to diversify away from Keytruda. Privately, though, deal insiders acknowledge that competitive heat, especially from Pfizer and AstraZeneca, both eyeing similar bispecific assets, forced Merck’s hand, speeding up a decision they might’ve otherwise drawn out.
Looked at in isolation, this purchase might seem reckless. But stacked against the looming Keytruda patent cliff, think $15 billion at risk by 2028, and the fierce pace of innovation in immuno-oncology, the deal is less about near-term earnings and more about holding ground with payers and PBMs. The real test will play out in formulary rankings and oncology reimbursement trends, which can be monitored live at RxPBM.ai. Merck is placing a big bet on its ability to turn a zero-revenue asset into a blockbuster. For context, they've only managed that twice in the last ten years, a reminder that pharma’s “big swings” rarely land without turbulence.
Lilly’s Surprise FDA Setback Hits Obesity Launch Plans
Mid-week, Eli Lilly got hit with a surprise Complete Response Letter (CRL) from the FDA for its much-hyped obesity biologic, retatrutide. Officially, the letter cited manufacturing issues at a third-party facility. Unofficially? Industry sources say it’s the single-dose pen delivery system that’s the problem, stability tests flagged higher-than-expected particulates. The result: Lilly shares plunged 7% immediately, erasing over $30 billion in market cap within hours.
Why does this sting so much for Lilly? Retatrutide had been all but scheduled for a late 2024 launch, with Wall Street expecting $2.5 billion in first-year sales. Now, a six to nine-month remediation window hands more space to Novo Nordisk’s Wegovy, while payers will keep slow-walking reimbursement for new GLP-1s. The CRL also sparked deeper conversations about just how complex it is to manufacture, scale, and deliver injectable biologics as demand for these the GLP-1s continues outpacing supply. For anyone tracking pipeline and timelines, there’s a full overview at ClinicalRx.ai.
Specialty pharmacies are left holding the bag, for now. They’ll keep facing the same capacity headaches with Wegovy and Ozempic. Pricing power? Still with the incumbents. Efforts to get access for Lilly’s new entrant face fresh delays, which impacts both patients and the pharmacies themselves. If you’re in operations, expect more of the same chaos, just extended, hardly an enviable position.
Earnings Season Paints a Stark New Picture Post-IRA
Q2 earnings brought a mixed bag for large pharma. Bristol Myers Squibb missed consensus by 11%, citing weaker Revlimid sales after generics accelerated their push, thanks to Medicare’s tighter negotiation rules. Meanwhile, Pfizer pulled off a surprise, squeezing an extra $600 million in COVID wind-down savings and seeing unexpectedly strong uptake for its updated RSV vaccine among the 60-plus set. The winners and losers are shifting fast.
Beneath the headlines, the more granular trend is hard to ignore: branded net pricing in the US, flat to down 2% year-over-year across the top 10 pharmas. That figure’s right there on RxInfo.ai. No major player could push list price increases that stuck, a testament to evolving PBM leverage and the slow-rolling effects of IRA inflation caps, especially for portfolios exposed to Part D.
Manufacturers now face pressure to rethink gross-to-net forecasting and sharpen their specialty channel strategies, particularly for drugs near Medicare negotiation eligibility. Several investor Q&As zeroed in on the nuts and bolts of “blend and extend” rebates, and what happens as patient support and copay card programs have to flex with wider list-to-net spreads. For employers and pharmacies, the message is clear: brace for more adjudication complexity, more appeals, and higher administrative costs. The acceleration of cost-shifting is already showing up in the numbers at RxBenefits.ai. It’s getting messy, just part of the new normal.
Pipeline Shocks and Regulatory Scrambling Are Redefining Risk
The headlines don’t cover everything. Underneath, the FDA’s docket this week was packed with first-in-class reviews and the kind of labeling disputes that create ripples for years. One hot spot: the split advisory vote on Novartis’ inclisiran indication expansion. New real-world evidence halved the absolute event reduction seen in trials, which set off a heated debate about efficacy in moderate-risk populations. The result? Not a rejection, but certainly a chill. Novartis’ stock barely moved even after a lukewarm panel vote, a clear sign investors aren’t buying near-term upside just yet.
It’s becoming clear: pipeline volatility is here for the long haul as regulators demand ever-more granular real-world data and post-market evidence, especially as payers clamp down on reimbursement for anything without “hard” outcomes. Manufacturers are now staring down pricier monitoring, ballooning data costs, and slower launches across cardiometabolic and autoimmune categories. For smaller players, this means deal values hinge on data that might be outmoded or irrelevant by the time a transaction closes, a brutal reality check, but that’s the game right now.
And for pharmacists and supply chain operators? Clinical knowledge alone won’t cut it. Payment systems, coverage logic, and operational headaches morph as fast as the science, sometimes faster. This week’s twists proved, again, that even the best pipeline or commercialization plan can unravel overnight with a regulatory surprise or a rival’s bold move. I’ll say it: agility and a bit of nerve are what separate the survivors from the sidelined. There’s not much more to add. That’s where we are, and where we’ll probably stay for the foreseeable future.
